academic article

• Ofatumumab versus Teriflunomide in Multiple Sclerosis..  The New England journal of medicine.  383:546-557. 2020
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta..  Lancet neurology.  9:381-390. 2010